NHS Approves Life-Changing Treatments for Children with Spinal Muscular Atrophy

NHS England has announced the routine availability of two groundbreaking treatments, nusinersen and risdiplam, for children suffering from spinal muscular atrophy (SMA), a rare genetic condition causing progressive muscle weakness. This decision follows approval by the National Institute for Health and Care Excellence (NICE) and a commercial agreement ensuring lifelong access for eligible patients. Nusinersen is administered via spinal injection, while risdiplam is taken orally at home. Clinical data from SMA REACH UK indicates that these medications significantly improve survival rates, with 73 children with severe Type 1 SMA surviving beyond age five. NHS officials describe the rollout as a phenomenal step forward, offering hope to families who previously faced grim prognoses. Approximately 70 babies are born with SMA in the UK annually, affecting around 1,150 people in England. The announcement highlights the potential for patients to maintain independence, communicate effectively, and reduce hospital dependency. Public awareness of SMA has recently increased due to high-profile cases, including the diagnosis of singer Jesy Nelson’s twins. This development marks a significant advancement in specialized healthcare services for rare diseases in the UK.